How the Renin-Angiotensin System Controls Your Kidneys
Kidney Peptides
1.7 liters/min
Your kidneys filter approximately 1.7 liters of blood per minute, and the renin-angiotensin system controls the pressure that drives this filtration.
StatPearls, Physiology: Renin Angiotensin System, 2024
StatPearls, Physiology: Renin Angiotensin System, 2024
View as imageYour kidneys receive about 20% of your cardiac output every minute, far more blood per gram of tissue than any other organ. The renin-angiotensin-aldosterone system (RAAS) is the peptide-based control system that determines how much blood the kidneys receive, how much sodium they retain, and how much water follows that sodium back into the bloodstream. When this system malfunctions, hypertension and chronic kidney disease follow. When it is pharmacologically blocked with ACE inhibitors or ARBs, kidney decline slows and cardiovascular events decrease. For an overview of the peptide systems governing kidney function, see our guide to kidney peptides and water balance.
The RAAS is, at its core, a peptide cascade. A protein enzyme (renin) cleaves a protein substrate (angiotensinogen) to produce angiotensin I, a 10-amino-acid peptide. Another enzyme (ACE) clips two amino acids off to produce angiotensin II, an 8-amino-acid peptide that is one of the most potent vasoconstrictors in human physiology. Every step is a peptide transformation, and every major drug class that targets hypertension or kidney disease intervenes at one of these steps.
Key Takeaways
- The RAAS cascade begins when juxtaglomerular cells in the kidney release renin in response to low blood pressure, low sodium delivery, or sympathetic nervous system activation
- Angiotensin II constricts the efferent arteriole more than the afferent, maintaining glomerular filtration pressure even when systemic blood pressure drops
- ACE inhibitors and ARBs reduce proteinuria by 30 to 40% and slow progression of diabetic nephropathy, independent of their blood pressure effects[1]
- ACE2 converts angiotensin II into angiotensin (1-7), a vasodilatory peptide that opposes angiotensin II's effects on the kidney[4]
- The prorenin receptor amplifies local RAS activity in the kidney, contributing to fibrosis and inflammation independently of angiotensin II[3]
- Food-derived peptides from dairy, fish, and plant sources can inhibit ACE in vitro, though clinical blood pressure effects are modest compared to pharmaceutical ACE inhibitors[7]
The Three Sensors That Start the Cascade
Renin release is the rate-limiting step of the entire RAAS. The juxtaglomerular (JG) cells, specialized smooth muscle cells in the walls of the afferent arterioles entering each glomerulus, serve as the kidney's blood pressure sensors. Three distinct mechanisms trigger renin release:
The baroreceptor mechanism. JG cells are stretch-sensitive. When blood pressure in the afferent arteriole drops, the reduced stretch on JG cell membranes triggers renin secretion. When pressure rises, stretch increases and renin release is suppressed. This is the most direct and fastest sensor.
The macula densa mechanism. The macula densa is a patch of specialized epithelial cells in the distal convoluted tubule, positioned where it passes between the afferent and efferent arterioles of its own glomerulus. These cells monitor sodium chloride concentration in the tubular fluid. Low NaCl delivery signals that upstream filtration or absorption is altered, triggering the macula densa to release prostaglandins and nitric oxide that stimulate JG cells to release renin.
Sympathetic nervous system activation. Beta-1 adrenergic receptors on JG cells respond to sympathetic nerve input. During hemorrhage, dehydration, or heart failure, increased sympathetic tone directly stimulates renin release, independent of renal perfusion pressure. This pathway connects the kidney's local control system to the body's systemic stress response.
These three sensors provide redundant coverage: the kidney can detect and respond to low blood pressure through direct pressure sensing, tubular flow sensing, and systemic neural signaling. All three converge on the same response: more renin, more angiotensin II, higher blood pressure, more sodium retention.
The Peptide Cascade: From Angiotensinogen to Angiotensin II
Once released into the bloodstream, renin cleaves angiotensinogen, a large glycoprotein produced continuously by the liver. The product is angiotensin I, a decapeptide (10 amino acids) with minimal biological activity. Angiotensin I is essentially a pro-peptide, a placeholder waiting for activation.
That activation comes from angiotensin-converting enzyme (ACE), a membrane-bound zinc metalloprotease found predominantly on the surface of endothelial cells in the pulmonary vasculature. As blood carrying angiotensin I passes through the lungs, ACE removes the C-terminal dipeptide (His-Leu), producing angiotensin II, an octapeptide (8 amino acids: Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) with potent biological activity.[1]
ACE is not limited to the lungs. It is expressed on endothelial surfaces throughout the body and is particularly abundant in the kidney, where local ACE activity generates angiotensin II within the renal tissue itself. This intrarenal RAS operates independently of circulating angiotensin II, meaning the kidney can regulate its own angiotensin II levels locally, even when systemic levels are suppressed by ACE inhibitors.
ACE also degrades bradykinin, a vasodilatory peptide. This dual function means ACE inhibitors both reduce angiotensin II production and increase bradykinin levels, contributing to their vasodilatory effect but also explaining the persistent dry cough that affects 5 to 20% of patients on these drugs.
What Angiotensin II Does in the Kidney
Angiotensin II acts through two receptor subtypes: AT1 and AT2. The AT1 receptor mediates nearly all of angiotensin II's classic effects on blood pressure and kidney function. The AT2 receptor generally opposes AT1 signaling, promoting vasodilation and natriuresis, though its role in normal physiology is less dominant.
At the glomerulus, angiotensin II preferentially constricts the efferent arteriole (the vessel leaving the glomerulus) more than the afferent arteriole (the vessel entering). This differential constriction is critical. By narrowing the exit pathway, angiotensin II increases hydrostatic pressure within the glomerular capillaries, maintaining the pressure gradient that drives filtration even when systemic blood pressure has dropped. Without this mechanism, every episode of mild hypotension would reduce glomerular filtration rate (GFR) and compromise kidney function.
In the proximal tubule, angiotensin II stimulates the sodium-hydrogen exchanger (NHE3), increasing sodium reabsorption. More sodium reabsorption means more water follows osmotically, expanding plasma volume and raising blood pressure. This is the kidney's primary mechanism for long-term blood pressure regulation: controlling sodium balance controls fluid volume, which controls blood pressure.
Angiotensin II also stimulates aldosterone release from the adrenal cortex. Aldosterone acts on the collecting duct to increase sodium reabsorption and potassium secretion through epithelial sodium channels (ENaC). This aldosterone-mediated sodium retention represents a second, slower layer of the RAS response.
When the RAS Goes Wrong: Kidney Disease and Hypertension
Chronic overactivation of the RAAS is a central driver of hypertension and progressive kidney damage. In conditions like diabetic nephropathy, the intrarenal RAS becomes overactive. Excessive angiotensin II within kidney tissue causes sustained efferent arteriolar constriction, which initially maintains GFR but eventually causes glomerular hyperfiltration, the forceful pushing of plasma through the glomerular basement membrane at above-normal pressures.
Hyperfiltration damages the glomerular capillaries, causing them to leak proteins (proteinuria) and activating inflammatory and fibrotic pathways. Angiotensin II directly stimulates transforming growth factor-beta (TGF-beta) production, which promotes collagen deposition and fibrosis in the renal interstitium. Over years, this process replaces functional kidney tissue with scar tissue. A 2026 study on RAS activation and oxidative stress in hospitalized patients confirmed that elevated markers of RAS activity correlate with increased oxidative damage in kidney tissue.[5]
The prorenin receptor adds another layer to this pathology. Beyond activating the RAS cascade, the prorenin receptor triggers intracellular signaling pathways (MAP kinase and Wnt/beta-catenin) that promote fibrosis and inflammation independently of angiotensin II. A 2025 study demonstrated that prorenin receptor blockade prevented blood pressure increases and reduced renal injury markers, suggesting this receptor is an independent therapeutic target.[3]
For a deeper look at how the peptide angiotensin II functions beyond the kidney, see our dedicated article.
ACE Inhibitors and ARBs: Blocking the Cascade
The clinical importance of the RAAS was proven by the success of its inhibitors. ACE inhibitors (enalapril, lisinopril, ramipril) and angiotensin receptor blockers (losartan, valsartan, telmisartan) are among the most prescribed medications worldwide.
A systematic analysis of ACE and hypertension found that these drugs reduce proteinuria by 30 to 40% in patients with diabetic kidney disease, an effect that persists beyond what blood pressure reduction alone would explain.[1] This renoprotective effect stems from reducing efferent arteriolar constriction. By blocking angiotensin II's preferential constriction of the efferent arteriole, these drugs lower intraglomerular pressure, reducing hyperfiltration and protein leakage.
Angiotensin receptor-neprilysin inhibitors (ARNIs), combining an ARB with a neprilysin inhibitor (sacubitril/valsartan), represent the newest class of RAS-targeting drugs. A 2024 efficacy review of ARNIs found improved renal outcomes in heart failure patients, with reduced rates of kidney function decline compared to ACE inhibitors alone.[2] Neprilysin inhibition prevents the breakdown of natriuretic peptides, which counterbalance the RAAS by promoting sodium excretion and vasodilation.
The connection to the erythropoietin system is worth noting: chronic kidney disease impairs erythropoietin production alongside RAAS dysregulation, linking blood pressure control and red blood cell production through shared renal pathology.
The Counter-Regulatory Arm: ACE2 and Angiotensin (1-7)
The RAAS is not a one-directional escalator. A counter-regulatory axis, centered on ACE2, opposes angiotensin II's vasoconstrictive and pro-fibrotic effects. ACE2 cleaves a single amino acid from angiotensin II, producing angiotensin (1-7), a heptapeptide that acts on the Mas receptor to promote vasodilation, reduce inflammation, and oppose fibrosis.
Wang and colleagues (2016) demonstrated that ACE2 metabolizes and partially inactivates multiple peptide substrates beyond angiotensin II, functioning as a broader regulatory enzyme in peptide metabolism.[4] In the kidney, the ACE2/angiotensin (1-7)/Mas axis promotes natriuresis (sodium excretion), opposes fibrosis, and protects podocytes (the specialized cells that form the glomerular filtration barrier).
The balance between ACE/angiotensin II/AT1 and ACE2/angiotensin (1-7)/Mas determines the net effect of the RAS on the kidney at any given time. In healthy kidneys, these arms are balanced. In diabetic nephropathy and hypertensive kidney disease, the balance shifts toward the ACE/angiotensin II axis, with reduced ACE2 expression and lower angiotensin (1-7) levels. This has fueled interest in recombinant ACE2 and angiotensin (1-7) analogs as therapeutic agents, though none have reached clinical approval for kidney disease.
ACE2 gained global attention as the cell surface receptor for SARS-CoV-2, the virus responsible for COVID-19. The virus binds ACE2 to enter cells, potentially reducing ACE2 activity and shifting the RAAS balance toward angiotensin II-driven inflammation and fibrosis. This partly explains the kidney injury observed in severe COVID-19 cases.
Food-Derived ACE-Inhibitory Peptides
Beyond pharmaceutical ACE inhibitors, a substantial body of research has identified peptides from food proteins that inhibit ACE activity in vitro. Peptides from milk (casein and whey), fish (sardine, bonito), soybeans, and other plant sources have demonstrated ACE-inhibitory activity in laboratory assays.[7]
The tripeptides Ile-Pro-Pro (IPP) and Val-Pro-Pro (VPP) from fermented milk are the most studied, with meta-analyses showing modest blood pressure reductions of approximately 3 to 5 mmHg systolic in hypertensive individuals. Novel peptides continue to be identified: a 2025 study characterized a highly active ACE-inhibitory peptide from food protein sources with IC50 values in the micromolar range.[8]
The clinical significance of food-derived ACE-inhibitory peptides remains limited compared to pharmaceutical ACE inhibitors. Bioavailability is a major challenge: oral peptides must survive gastric digestion, intestinal absorption, and hepatic metabolism before reaching the vasculature. Most food-derived peptides show strong in vitro ACE inhibition but minimal in vivo blood pressure effects at realistic dietary doses. For a broader look at food sources, see our article on food-derived peptides for blood pressure and the specific case of dairy-derived blood pressure peptides.
The Bottom Line
The renin-angiotensin-aldosterone system is a peptide cascade that controls kidney blood flow, glomerular filtration, and sodium balance. Angiotensin II, its primary effector, preferentially constricts the efferent arteriole to maintain filtration pressure. When chronically overactive, this same mechanism drives hypertension and progressive kidney damage through hyperfiltration and fibrosis. ACE inhibitors and ARBs slow kidney decline by reducing intraglomerular pressure, while the counter-regulatory ACE2/angiotensin (1-7) axis opposes these effects. Understanding the RAAS as a peptide system reveals why it remains the most important pharmacological target in kidney disease.